Advertisement

Travel and Transplantation

  • Camille Nelson Kotton
  • José G. MontoyaEmail author
Chapter

Abstract

As organ transplant recipients live longer and healthier lives after transplant, they increasingly partake in foreign travel, for leisure, adventure, work, or to visit friends or relatives. A review of cohorts of transplant recipients shows that they tend to have minimal or suboptimal preparation prior to travel, with limited pre-travel vaccination, medications, and education, and overall poses greatly increased risk of travel-related infections and complications. Enhancing the knowledge of the transplant recipients is likely to result in better safety and outcomes for these vulnerable patients. This chapter covers optimal vaccination prior to travel, use of travel-related medications with information on drug interactions, specific educational topics, and details regarding additional resources.

Keywords

Travel Transplant Tropical disease Malaria 

References

  1. 1.
    Boggild AK, Sano M, Humar A, Salit I, Gilman M, Kain KC. Travel patterns and risk behavior in solid organ transplant recipients. J Travel Med. 2004;11(1):37–43.PubMedGoogle Scholar
  2. 2.
    Uslan DZ, Patel R, Virk A. International travel and exposure risks in solid-organ transplant recipients. Transplantation. 2008;86(3):407–12.PubMedGoogle Scholar
  3. 3.
    Roukens AH, van Dissel JT, de Fijter JW, Visser LG. Health preparations and travel-related morbidity of kidney transplant recipients traveling to developing countries. Clin Transpl. 2007;21(4):567–70.Google Scholar
  4. 4.
    Kotton CN, Kroger AT, Feedman D. Immunocompromised Travelers – Chapter 8 – 2018 Yellow Book | Travelers’ Health | CDC. https://wwwnc.cdc.gov/travel/yellowbook/2018/advising-travelers-with-specific-needs/immunocompromised-travelers. Published 2017.
  5. 5.
    The immunocompromised traveller. An Advisory Committee Statement (ACS). Can Commun Dis Rep. 2007;33(ACS-4):1–24.Google Scholar
  6. 6.
    Centers for Disease Control Health Information for International Travel. Atlanta, GA; 2018 [cited 2019 April 22]. Available from: https://wwwnc.cdc.gov/travel/page/yellowbook-home.
  7. 7.
    Ryan ET, Kain KC. Health advice and immunizations for travelers. N Engl J Med. 2000;342(23):1716–25.PubMedGoogle Scholar
  8. 8.
    Panackal AA, Hajjeh RA, Cetron MS, Warnock DW. Fungal infections among returning travelers. Clin Infect Dis. 2002;35(9):1088–95.PubMedGoogle Scholar
  9. 9.
    Hart J, Dyer JR, Clark BM, McLellan DG, Perera S, Ferrari P. Travel-related disseminated Penicillium marneffei infection in a renal transplant patient. Transpl Infect Dis. 2012;14:434–9.PubMedGoogle Scholar
  10. 10.
    Prasad N, Bhadauria D, Sharma RK, Gupta A, Kaul A, Srivastava A. Dengue virus infection in renal allograft recipients: a case series during 2010 outbreak. Transpl Infect Dis. 2012;14(2):163–8.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Geyer M, Wilpert J, Wiech T, Theilacker C, Stubanus M, Kramer-Zucker A, et al. Rapidly progressive hepatic alveolar echinococcosis in an ABO-incompatible renal transplant recipient. Transpl Infect Dis. 2011;13:278–84.PubMedGoogle Scholar
  12. 12.
    Hackett PH, Roach RC. High-altitude illness. N Engl J Med. 2001;345(2):107–14.PubMedGoogle Scholar
  13. 13.
    Pirenne J, Van Gelder F, Kharkevitch T, Nevens F, Verslype C, Peetermans WE, et al. Tolerance of liver transplant patients to strenuous physical activity in high-altitude. Am J Transplant. 2004;4(4):554–60.PubMedGoogle Scholar
  14. 14.
    Roi GS, Mosconi G, Capelli I, Cuna V, Persici E, Parigino M, et al. Alpine skiing and anaerobic performance in solid organ transplant recipients. Transplant Proc. 2010;42(4):1029–31.PubMedGoogle Scholar
  15. 15.
    Ghafur A, Raza M, Labbett W, Chawla A, Smith C, Ngui SL, et al. Travel-associated acquisition of hepatitis C virus infection in patients receiving haemodialysis. Nephrol Dial Transplant. 2007;22(9):2640–4.PubMedGoogle Scholar
  16. 16.
    Coward RA, Garrues M, Solomon LR, Gibson SP. Hepatitis C and holiday dialysis. A postal survey of UK renal units. Nephrol Dial Transplant. 2000;15(10):1715.PubMedGoogle Scholar
  17. 17.
    Parsons D, Coward RA, Woywodt A. Travel-associated acquisition of hepatitis C-- implications for the renal transplant waiting list. Nephrol Dial Transplant. 2008;23(6):2104; author reply −5PubMedGoogle Scholar
  18. 18.
    Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357(25):2601–14.PubMedPubMedCentralGoogle Scholar
  19. 19.
    van der Velden AM, Claessen AM, van Velzen-Blad H, de Groot MR, Kramer MH, Biesma DH, et al. Vaccination responses and lymphocyte subsets after autologous stem cell transplantation. Vaccine. 2007;25(51):8512–7.PubMedGoogle Scholar
  20. 20.
    Magnani G, Falchetti E, Pollini G, Reggiani LB, Grigioni F, Coccolo F, et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study. J Heart Lung Transplant. 2005;24(5):588–92.PubMedGoogle Scholar
  21. 21.
    Nevens F, Zuckerman JN, Burroughs AK, Jung MC, Bayas JM, Kallinowski B, et al. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients. Liver Transpl. 2006;12(10):1489–95.PubMedGoogle Scholar
  22. 22.
    Rosenau J, Hooman N, Rifai K, Solga T, Tillmann HL, Grzegowski E, et al. Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. Transpl Int. 2006;19(10):828–33.PubMedGoogle Scholar
  23. 23.
    Kumar D, Blumberg EA, Danziger-Isakov L, Kotton CN, Halasa NB, Ison MG, et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations(dagger). Am J Transplant. 2011;11(10):2020–30.PubMedGoogle Scholar
  24. 24.
    Roush SW, Murphy TV. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA. 2007;298(18):2155–63.PubMedGoogle Scholar
  25. 25.
    Henning KJ, White MH, Sepkowitz KA, Armstrong D. A national survey of immunization practices following allogeneic bone marrow transplantation. JAMA. 1997;277(14):1148–51.PubMedGoogle Scholar
  26. 26.
    Recommended Adult Immunization Schedule for ages 19 years or older, United States 2019, Available at: https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html. MMWR Morb Mortal Wkly Rep. 2019;68(5):115–8.
  27. 27.
    Danziger-Isakov L, Kumar D, AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;19:e13563.Google Scholar
  28. 28.
    Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant. 2008;8(1):9–14.PubMedGoogle Scholar
  29. 29.
    Ballout A, Goffin E, Yombi JC, Vandercam B. Vaccinations for adult solid organ transplant recipient: current recommendations. Transplant Proc. 2005;37(6):2826–7.PubMedGoogle Scholar
  30. 30.
    Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev. 2003;16(3):357–64.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Kotton CN, Ryan ET, Fishman JA. Prevention of infection in adult travelers after solid organ transplantation. Am J Transplant. 2005;5(1):8–14.PubMedGoogle Scholar
  32. 32.
    Kotton CN. Vaccination and immunization against travel-related diseases in immunocompromised hosts. Expert Rev Vaccines. 2008;7(5):663–72.PubMedGoogle Scholar
  33. 33.
    Buchan CA, Kotton CN, AST Infectious Diseases Community of Practice. Travel medicine, transplant tourism, and the solid organ transplant recipient-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019:e13529.Google Scholar
  34. 34.
    Ljungman P, Cordonnier C, Einsele H, Englund J, Machado CM, Storek J, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009;44(8):521–6.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Machado CM. Reimmunization after hematopoietic stem cell transplantation. Expert Rev Vaccines. 2005;4(2):219–28.PubMedGoogle Scholar
  36. 36.
    Leung AY, Chow HC, Kwok JS, Lui CK, Cheng VC, Yuen KY, et al. Safety of vaccinating sibling donors with live-attenuated varicella zoster vaccine before hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;39(11):661–5.PubMedGoogle Scholar
  37. 37.
    Storek J, Viganego F, Dawson MA, Herremans MM, Boeckh M, Flowers ME, et al. Factors affecting antibody levels after allogeneic hematopoietic cell transplantation. Blood. 2003;101(8):3319–24.PubMedGoogle Scholar
  38. 38.
    Sever MS, Kazancioglu R, Yildiz A, Turkmen A, Ecder T, Kayacan SM, et al. Outcome of living unrelated (commercial) renal transplantation. Kidney Int. 2001;60(4):1477–83.PubMedGoogle Scholar
  39. 39.
    Kumar D, Welsh B, Siegal D, Chen MH, Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients--three year follow-up of a randomized trial. Am J Transplant. 2007;7(3):633–8.PubMedGoogle Scholar
  40. 40.
    Avery RK, Ljungman P. Prophylactic measures in the solid-organ recipient before transplantation. Clin Infect Dis. 2001;33(Suppl 1):S15–21.PubMedGoogle Scholar
  41. 41.
    Molrine DC, Hibberd PL. Vaccines for transplant recipients. Infect Dis Clin N Am. 2001;15(1):273–305. xiiGoogle Scholar
  42. 42.
    Gershman M, Staples JE. Chap. 3: Infectious diseases related to travel: yellow fever. 2012 Health Information for International Travel (available at wwwnccdcgov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/yellow-feverhtm). 2012 ed. Atlanta: Centers for Disease Control and Prevention. 2012.Google Scholar
  43. 43.
    Rand EB, McCarthy CA, Whitington PF. Measles vaccination after orthotopic liver transplantation. J Pediatr. 1993;123(1):87–9.PubMedGoogle Scholar
  44. 44.
    Hayney MS, Welter DL, Reynolds AM, Francois M, Love RB. High-dose hepatitis B vaccine in patients waiting for lung transplantation. Pharmacotherapy. 2003;23(5):555–60.PubMedGoogle Scholar
  45. 45.
    Bienzle U, Gunther M, Neuhaus R, Vandepapeliere P, Vollmar J, Lun A, et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology. 2003;38(4):811–9.PubMedGoogle Scholar
  46. 46.
    Choy BY, Peiris JS, Chan TM, Lo SK, Lui SL, Lai KN. Immunogenicity of intradermal hepatitis B vaccination in renal transplant recipients. Am J Transplant. 2002;2(10):965–9.PubMedGoogle Scholar
  47. 47.
    Jaffe D, Papadopoulos EB, Young JW, O’Reilly RJ, Prockop S, Kernan NA, et al. Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood. 2006;108(7):2470–5.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Ljungman P, Wang FZ, Nilsson C, Solheim V, Linde A. Vaccination of autologous stem cell transplant recipients with live varicella vaccine: a pilot study. Support Care Cancer. 2003;11(11):739–41.PubMedGoogle Scholar
  49. 49.
    Mutsch M, Spicher VM, Gut C, Steffen R. Hepatitis A virus infections in travelers, 1988–2004. Clin Infect Dis. 2006;42(4):490–7.PubMedGoogle Scholar
  50. 50.
    Arslan M, Wiesner RH, Poterucha JJ, Zein NN. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation. 2001;72(2):272–6.Google Scholar
  51. 51.
    Dumot JA, Barnes DS, Younossi Z, Gordon SM, Avery RK, Domen RE, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol. 1999;94(6):1601–4.PubMedGoogle Scholar
  52. 52.
    Stark K, Gunther M, Neuhaus R, Reinke P, Schroder K, Linnig S, et al. Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. J Infect Dis. 1999;180(6):2014–7.PubMedGoogle Scholar
  53. 53.
    Gunther M, Stark K, Neuhaus R, Reinke P, Schroder K, Bienzle U. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation. 2001;71(3):477–9.PubMedGoogle Scholar
  54. 54.
    Rendi-Wagner P, Korinek M, Winkler B, Kundi M, Kollaritsch H, Wiedermann U. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine. 2007;25(5):927–31.PubMedGoogle Scholar
  55. 55.
    World Health Organization: Initiative for Vaccine Research: Typhoid Fever. [cited April 27, 2008]; Available from: http://www.who.int/vaccine_research/diseases/diarrhoeal/en/index7.html.
  56. 56.
    Begier EM, Burwen DR, Haber P, Ball R. Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002. Clin Infect Dis. 2004;38(6):771–9.PubMedGoogle Scholar
  57. 57.
    Ljungman P, Aschan J, Gustafsson B, Lewensohn-Fuchs I, Winiarski J, Ringden O. Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients. Bone Marrow Transplant. 2004;34(12):1067–9.PubMedGoogle Scholar
  58. 58.
    Mahler MB, Taur Y, Jean R, Kernan NA, Prockop SE, Small TN. Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(1):145–9.PubMedGoogle Scholar
  59. 59.
    Parkkali T, Kayhty H, Lehtonen H, Ruutu T, Volin L, Eskola J, et al. Tetravalent meningococcal polysaccharide vaccine is immunogenic in adult allogeneic BMT recipients. Bone Marrow Transplant. 2001;27(1):79–84.PubMedGoogle Scholar
  60. 60.
  61. 61.
  62. 62.
  63. 63.
    Cetron MS, Marfin AA, Julian KG, Gubler DJ, Sharp DJ, Barwick RS, et al. Yellow fever vaccine. recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep. 2002;51(RR-17):1–11. quiz CE1–4.PubMedGoogle Scholar
  64. 64.
    Fishman JA. Smallpox and live-virus vaccination in transplant recipients. Am J Transplant. 2003;3(7):786–93.PubMedGoogle Scholar
  65. 65.
    Ljungman P. Vaccination of transplant recipients. In: RA Bowden PL, Paya CV, editors. Transplant infections. Philadelphia: Lippincott Williams & Wilkins; 2003. p. 611–24.Google Scholar
  66. 66.
    Mileno M. Preparation of immunocompromised travelers. In: JS Keystone PK, Freedman DP, Nothdurft HD, Connor BA, editors. Travel medicine. 1st ed. Edinburgh: Mosby; 2004. p. 249–55.Google Scholar
  67. 67.
    Gowda R, Cartwright K, Bremner JA, Green ST. Yellow fever vaccine: a successful vaccination of an immunocompromised patient. Eur J Haematol. 2004;72(4):299–301.PubMedGoogle Scholar
  68. 68.
    Receveur MC, Thiebaut R, Vedy S, Malvy D, Mercie P, Bras ML. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. Clin Infect Dis. 2000;31(3):E7–8.PubMedGoogle Scholar
  69. 69.
    Tattevin P, Depatureaux AG, Chapplain JM, Dupont M, Souala F, Arvieux C, et al. Yellow fever vaccine is safe and effective in HIV-infected patients. AIDS. 2004;18(5):825–7.PubMedGoogle Scholar
  70. 70.
    Ho YL, Enohata T, Lopes MH, De Sousa Dos Santos S. Vaccination in Brazilian HIV-infected adults: a cross-sectional study. AIDS Patient Care STDs 2007.Google Scholar
  71. 71.
    Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thail. 2002;85(1):131–4.Google Scholar
  72. 72.
    Gibbons RV, Rupprecht CE. Postexposure rabies prophylaxis in immunosuppressed patients. JAMA. 2001;285(12):1574–5.PubMedGoogle Scholar
  73. 73.
    Tantawichien T, Jaijaroensup W, Khawplod P, Sitprija V. Failure of multiple-site intradermal postexposure rabies vaccination in patients with human immunodeficiency virus with low CD4+ T lymphocyte counts. Clin Infect Dis. 2001;33(10):E122–4.PubMedGoogle Scholar
  74. 74.
    Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1993;42(RR-1):1–15.Google Scholar
  75. 75.
    Rojanasuphot S, Shaffer N, Chotpitayasunondh T, Phumiamorn S, Mock P, Chearskul S, et al. Response to JE vaccine among HIV-infected children, Bangkok, Thailand. Southeast Asian J Trop Med Public Health. 1998;29(3):443–50.PubMedGoogle Scholar
  76. 76.
    Puthanakit T, Aurpibul L, Yoksan S, Sirisanthana T, Sirisanthana V. Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine. 2007;25(49):8257–61.PubMedGoogle Scholar
  77. 77.
    Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-4):1–40.PubMedGoogle Scholar
  78. 78.
    Centers for Disease Control Travelers Health website. Available at wwwnc.cdc.gov/travel/destinations/list.htm.
  79. 79.
    Freedman DO, Weld LH, Kozarsky PE, Fisk T, Robins R, von Sonnenburg F, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med. 2006;354(2):119–30.PubMedGoogle Scholar
  80. 80.
    Aardema H, Sijpkens YW, Visser LG. Pancytopenia in a simultaneous pancreas and kidney transplant recipient: an unexpected cause – a case of visceral leishmaniasis in a transplant recipient. Clin Nephrol. 2009;71(4):460–2.PubMedGoogle Scholar
  81. 81.
    Rappo U, Beitler JR, Faulhaber JR, Firoz B, Henning JS, Thomas KM, et al. Expanding the horizons of histoplasmosis: disseminated histoplasmosis in a renal transplant patient after a trip to Bangladesh. Transpl Infect Dis. 2010;12(2):155–60.PubMedGoogle Scholar
  82. 82.
    Fernando RR, Krishnan S, Fairweather MG, Ericsson CD. Vibrio parahemolyticus septicaemia in a liver transplant patient: a case report. J Med Case Rep. 2011;5:171.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Pinsai S, Kiertiburanakul S, Watcharananan SP, Kantachuvessiri S, Boongird S, Bruminhent J. Epidemiology and outcomes of dengue in kidney transplant recipients: a 20-year retrospective analysis and comparative literature review. Clin Transplant. 2019;33(1):e13458.PubMedGoogle Scholar
  84. 84.
    Kumar D, Ferreira VH, Blumberg E, Silveira F, Cordero E, Perez-Romero P, Aydillo T, Danziger-Isakov L, Limaye AP, Carratala J, Munoz P, Montejo M, Lopez-Medrano F, Farinas MC, Gavalda J, Moreno A, Levi M, Fortun J, Torre-Cisneros J, Englund JA, Natori Y, Husain S, Reid G, Sharma TS, Humar A. A 5-year prospective multicenter evaluation of influenza infection in transplant recipients. Clin Infect Dis. 2018;67(9):1322–9.PubMedGoogle Scholar
  85. 85.
    Cordero E, Roca-Oporto C, Bulnes-Ramos A, Aydillo T, Gavaldà J, Moreno A, Torre-Cisneros J, Montejo JM, Fortun J, Muñoz P, Sabé N, Fariñas MC, Blanes-Julia M, López-Medrano F, Suárez-Benjumea A, Martinez-Atienza J, Rosso-Fernández C, Pérez-Romero P. TRANSGRIPE 1–2 Study Group. Two doses of inactivated influenza vaccine improve immune response in solid organ transplant recipients: results of TRANSGRIPE 1-2, a randomized controlled clinical trial. Clin Infect Dis. 2017;64(7):829–38.  https://doi.org/10.1093/cid/ciw855.PubMedGoogle Scholar
  86. 86.
    [No authors listed]. Shingrix – an adjuvanted, recombinant herpes zoster vaccine. Med Lett Drugs Ther. 2017;59(1535):195–6. PMID: 29186082Google Scholar
  87. 87.
    Nelson NP. Updated dosing instructions for immune globulin (human) GamaSTAN S/D for hepatitis A virus prophylaxis. MMWR Morb Mortal Wkly Rep. 2017;66:959–60.  https://doi.org/10.15585/mmwr.mm6636a5.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Transplant and Immunocompromised Host Infectious Diseases, Division of Infectious Diseases, Massachusetts General HospitalTravelers’ Advice and Immunization Center, Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical SchoolBostonUSA
  2. 2.Division of Infectious Diseases and Geographic MedicineStanford University School of MedicineStanfordUSA
  3. 3.Palo Alto Medical Foundation Toxoplasma Serology LaboratoryNational Reference Center for the Study and Diagnosis of ToxoplasmosisPalo AltoUSA

Personalised recommendations